StreetInsider.com News Articles

ORYZON Announces U.S. Patent Grant for Vafidemstat in Borderline Personality Disorder (BPD)

Wed, 08 Jul 2026 08:00:00 -0400

Granted claims cover the use of vafidemstat for treating non-aggressive symptoms of BPD
U.S. patent to expire in March 2043, including 1,095 days of Patent Term Adjustment
Notice of allowance also received in a corresponding Canadian patent application

MADRID and CAMBRIDGE, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 12,673,044, entitled “Methods of treating borderline personality disorder”. The

ORYZON Announces U.S. Patent Grant for Vafidemstat in Borderline Personality Disorder (BPD)

Wed, 08 Jul 2026 08:00:00 -0400

Granted claims cover the use of vafidemstat for treating non-aggressive symptoms of BPD
U.S. patent to expire in March 2043, including 1,095 days of Patent Term Adjustment
Notice of allowance also received in a corresponding Canadian patent application

ORYZON Announces U.S. Patent Grant for Vafidemstat in Borderline Personality Disorder (BPD)

Wed, 08 Jul 2026 08:00:00 -0400

Granted claims cover the use of vafidemstat for treating non-aggressive symptoms of BPD
U.S. patent to expire in March 2043, including 1,095 days of Patent Term Adjustment
Notice of allowance also received in a corresponding Canadian patent application

ORYZON Announces U.S. Patent Grant for Vafidemstat in Borderline Personality Disorder (BPD)

Wed, 08 Jul 2026 08:00:00 -0400

Granted claims cover the use of vafidemstat for treating non-aggressive symptoms of BPD
U.S. patent to expire in March 2043, including 1,095 days of Patent Term Adjustment
Notice of allowance also received in a corresponding Canadian patent application

ORYZON Announces U.S. Patent Grant for Vafidemstat in Borderline Personality Disorder (BPD)

Wed, 08 Jul 2026 08:00:00 -0400

Granted claims cover the use of vafidemstat for treating non-aggressive symptoms of BPD
U.S. patent to expire in March 2043, including 1,095 days of Patent Term Adjustment
Notice of allowance also received in a corresponding Canadian patent application

ORYZON Announces U.S. Patent Grant for Vafidemstat in Borderline Personality Disorder (BPD)

Wed, 08 Jul 2026 08:00:00 -0400

Granted claims cover the use of vafidemstat for treating non-aggressive symptoms of BPD
U.S. patent to expire in March 2043, including 1,095 days of Patent Term Adjustment
Notice of allowance also received in a corresponding Canadian patent application

ORYZON Announces U.S. Patent Grant for Vafidemstat in Borderline Personality Disorder (BPD)

Wed, 08 Jul 2026 08:00:00 -0400

Granted claims cover the use of vafidemstat for treating non-aggressive symptoms of BPD
U.S. patent to expire in March 2043, including 1,095 days of Patent Term Adjustment
Notice of allowance also received in a corresponding Canadian patent application

ORYZON Announces U.S. Patent Grant for Vafidemstat in Borderline Personality Disorder (BPD)

Wed, 08 Jul 2026 08:00:00 -0400

Granted claims cover the use of vafidemstat for treating non-aggressive symptoms of BPD
U.S. patent to expire in March 2043, including 1,095 days of Patent Term Adjustment
Notice of allowance also received in a corresponding Canadian patent application

ORYZON Announces U.S. Patent Grant for Vafidemstat in Borderline Personality Disorder (BPD)

Wed, 08 Jul 2026 08:00:00 -0400

Granted claims cover the use of vafidemstat for treating non-aggressive symptoms of BPD
U.S. patent to expire in March 2043, including 1,095 days of Patent Term Adjustment
Notice of allowance also received in a corresponding Canadian patent application

ORYZON Announces U.S. Patent Grant for Vafidemstat in Borderline Personality Disorder (BPD)

Wed, 08 Jul 2026 08:00:00 -0400

Granted claims cover the use of vafidemstat for treating non-aggressive symptoms of BPD
U.S. patent to expire in March 2043, including 1,095 days of Patent Term Adjustment
Notice of allowance also received in a corresponding Canadian patent application

ORYZON Announces U.S. Patent Grant for Vafidemstat in Borderline Personality Disorder (BPD)

Wed, 08 Jul 2026 08:00:00 -0400

Granted claims cover the use of vafidemstat for treating non-aggressive symptoms of BPD
U.S. patent to expire in March 2043, including 1,095 days of Patent Term Adjustment
Notice of allowance also received in a corresponding Canadian patent application

ORYZON Announces U.S. Patent Grant for Vafidemstat in Borderline Personality Disorder (BPD)

Wed, 08 Jul 2026 08:00:00 -0400

Granted claims cover the use of vafidemstat for treating non-aggressive symptoms of BPD
U.S. patent to expire in March 2043, including 1,095 days of Patent Term Adjustment
Notice of allowance also received in a corresponding Canadian patent application

ORYZON Announces U.S. Patent Grant for Vafidemstat in Borderline Personality Disorder (BPD)

Wed, 08 Jul 2026 08:00:00 -0400

Granted claims cover the use of vafidemstat for treating non-aggressive symptoms of BPD
U.S. patent to expire in March 2043, including 1,095 days of Patent Term Adjustment
Notice of allowance also received in a corresponding Canadian patent application

ORYZON Announces U.S. Patent Grant for Vafidemstat in Borderline Personality Disorder (BPD)

Wed, 08 Jul 2026 08:00:00 -0400

Granted claims cover the use of vafidemstat for treating non-aggressive symptoms of BPD
U.S. patent to expire in March 2043, including 1,095 days of Patent Term Adjustment
Notice of allowance also received in a corresponding Canadian patent application

ORYZON Announces U.S. Patent Grant for Vafidemstat in Borderline Personality Disorder (BPD)

Wed, 08 Jul 2026 08:00:00 -0400

Granted claims cover the use of vafidemstat for treating non-aggressive symptoms of BPD
U.S. patent to expire in March 2043, including 1,095 days of Patent Term Adjustment
Notice of allowance also received in a corresponding Canadian patent application

ORYZON Announces U.S. Patent Grant for Vafidemstat in Borderline Personality Disorder (BPD)

Wed, 08 Jul 2026 08:00:00 -0400

Granted claims cover the use of vafidemstat for treating non-aggressive symptoms of BPD
U.S. patent to expire in March 2043, including 1,095 days of Patent Term Adjustment
Notice of allowance also received in a corresponding Canadian patent application

Oryzon raises €12M in share offering, secures €25M COFIDES commitment

Wed, 01 Jul 2026 09:09:05 -0400

Oryzon Genomics, S.A. (ISIN: ES0167733015, ORY) completed a €12 million gross capital increase on July 1, 2026, through the issuance of 4,444,445 new ordinary shares priced at €2.70 per share.

The subscription price represents a 14.15% discount to the five-day volume-weighted average price of €3.1449 and a 12.68% discount to the June 30 closing price of €3.092. The offering was structured as a capital increase without the issuance of warrants. Singular Bank acted as placement agent in Spain, and All-Invest acted as placement agent in the EU and the UK.

According to a press release, proceeds will be directed toward advancing the

Oryzon raises €12M in share offering, secures €25M COFIDES commitment

Wed, 01 Jul 2026 09:09:05 -0400

Oryzon Genomics, S.A. (ISIN: ES0167733015, ORY) completed a €12 million gross capital increase on July 1, 2026, through the issuance of 4,444,445 new ordinary shares priced at €2.70 per share.

According to a press release, proceeds will be directed toward advancing the

Oryzon raises €12M in share offering, secures €25M COFIDES commitment

Wed, 01 Jul 2026 09:09:05 -0400

Oryzon Genomics, S.A. (ISIN: ES0167733015, ORY) completed a €12 million gross capital increase on July 1, 2026, through the issuance of 4,444,445 new ordinary shares priced at €2.70 per share.

According to a press release, proceeds will be directed toward advancing the

Oryzon raises €12M in share offering, secures €25M COFIDES commitment

Wed, 01 Jul 2026 09:09:05 -0400

Oryzon Genomics, S.A. (ISIN: ES0167733015, ORY) completed a €12 million gross capital increase on July 1, 2026, through the issuance of 4,444,445 new ordinary shares priced at €2.70 per share.

According to a press release, proceeds will be directed toward advancing the

Oryzon raises €12M in share offering, secures €25M COFIDES commitment

Wed, 01 Jul 2026 09:09:05 -0400

Oryzon Genomics, S.A. (ISIN: ES0167733015, ORY) completed a €12 million gross capital increase on July 1, 2026, through the issuance of 4,444,445 new ordinary shares priced at €2.70 per share.

According to a press release, proceeds will be directed toward advancing the

Oryzon raises €12M in share offering, secures €25M COFIDES commitment

Wed, 01 Jul 2026 09:09:05 -0400

Oryzon Genomics, S.A. (ISIN: ES0167733015, ORY) completed a €12 million gross capital increase on July 1, 2026, through the issuance of 4,444,445 new ordinary shares priced at €2.70 per share.

According to a press release, proceeds will be directed toward advancing the

Oryzon raises €12M in share offering, secures €25M COFIDES commitment

Wed, 01 Jul 2026 09:09:05 -0400

Oryzon Genomics, S.A. (ISIN: ES0167733015, ORY) completed a €12 million gross capital increase on July 1, 2026, through the issuance of 4,444,445 new ordinary shares priced at €2.70 per share.

According to a press release, proceeds will be directed toward advancing the

Oryzon raises €12M in share offering, secures €25M COFIDES commitment

Wed, 01 Jul 2026 09:09:05 -0400

Oryzon Genomics, S.A. (ISIN: ES0167733015, ORY) completed a €12 million gross capital increase on July 1, 2026, through the issuance of 4,444,445 new ordinary shares priced at €2.70 per share.

According to a press release, proceeds will be directed toward advancing the

ORYZON Raises €12 Million and Signs a Financing Agreement with COFIDES to Strengthen its Balance Sheet and Accelerate its Clinical Programs

Wed, 01 Jul 2026 09:08:00 -0400

Issued 4,444,445 new ordinary shares
Priced at €2.70 per share, representing a 14.15% discount on the five-day VWAP and a 12.68% discount to the June 30 closing price
The transaction has been structured as a capital increase without the issuance of warrants
Proceeds will be used to advance the Company's clinical development programs and support other corporate initiatives
The Social Impact Fund, managed by COFIDES, has committed to invest €25 million in future capital increases to support Oryzon's mental health programs, subject to certain conditions

MADRID and CAMBRIDGE, Mass., July 01, 2026